De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer.

Amelia Smith, Trinity College Dublin
Laura Murphy, Trinity College Dublin
Linda Sharp, Newcastle University
Darran O'Connor, Royal College of Surgeons in Ireland
William M. Gallagher, Newcastle University
Kathleen Bennett, Royal College of Surgeons in Ireland
Thomas I. Barron, Trinity College Dublin

Document Type Article

This article is also available at


BACKGROUND: Prior evidence suggests a role for statins in the management of cancer. However, the benefit of statin use in the adjuvant setting remains uncertain. This study investigates associations between statin use initiated after a breast cancer diagnosis and mortality.

METHODS: Women with stage I-III breast cancer were identified from the National Cancer Registry of Ireland (N=4243). Post-diagnostic statin initiators were identified from pharmacy claims data (N=837). Multivariate models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between de novo statin use and mortality.

RESULTS: The median duration of statin use was 6.7 years. No association was found between post-diagnostic statin use and breast cancer-specific (HR 0.88, 95% CI 0.66, 1.17) or all-cause mortality (HR 1.00, 95% CI 0.82, 1.21).

CONCLUSIONS: The results from our study suggest that initiating statin use after a diagnosis of stage I-III breast cancer is not associated with a reduction in breast cancer-specific mortality.